Actio Biosciences

From one to many — rare disease genetics unlocking common disease treatments

San Diego, United States · Founded 2021 · $121.0M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$121.0M
Last Round
$66.0M Series BJun 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Actio Biosciences is a clinical-stage biopharmaceutical company founded in October 2021 and headquartered in San Diego, California, focused on translating genetic insights into transformative medicines for both rare and common diseases. The company was co-founded by Dr. David Goldstein, a leading human geneticist who discovered over 30 disease-causing genes, and Dr. John McHutchison, former Chief Scientific Officer of Gilead Sciences, with a shared belief that understanding the genetics of rare diseases unlocks novel treatment approaches for far larger patient populations. Actio's pipeline targets neurological and genetic conditions, leveraging precision medicine and genomic tools developed by its founders at Columbia University, Gilead, and The Scripps Research Institute.

Summary

Actio Biosciences is a Biotech company based in San Diego, United States, founded in 2021. It has raised $121.0M in total across 2 rounds, most recently a $66.0M Series B round in Jun 2025. Investors include Deerfield Management, Regeneron Pharmaceuticals and Canaan Partners.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJun 2025
$66.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Actio Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/actio-biosciences"><img src="https://indexed.vc/api/badge/company/actio-biosciences" alt="Actio Biosciences on Indexed.vc" width="260" height="76" /></a>